Stay updated on Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page
- ChecktodayChange DetectedThe webpage has updated its date listings, removing older dates and adding new ones for May 2025.SummaryDifference0.4%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoChange DetectedThe webpage has added new dates, specifically April 8 and April 20 of 2025, and introduced a new biosimilar product, Pembrolizumab Biosimilar SB27. The previous dates of December 3 and December 27, 2024, have been removed.SummaryDifference0.6%
- Check22 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed descriptions of a phase II clinical trial for advanced melanoma treatments and the addition of new identifiers and revisions related to the study. The principal investigator's name has also been updated.SummaryDifference46%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to December 27, 2024.SummaryDifference0.4%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous estimated update date of December 27, 2024, and revision version 2.14.2.SummaryDifference0.2%
Stay in the know with updates to Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.